A University of Maryland spin-off venture called GlycoT Therapeutics LLC executed a sublicense agreement for its glycoengineering technology with major Japanese pharmaceutical company Daiichi Sankyo Company, Limited (Daiichi Sankyo). Actually a UM Ventures start-up company based on intellectual property developed at the University of Maryland, Baltimore (UMB), and University of Maryland, College Park (UMCP), this deal grants Daiichi Sankyo worldwide and non-exclusive rights to intellectual property that GlycoT currently licenses from UMB and UMCP, and includes an undisclosed upfront payment, annual fees, and adequate royalties of sales to GlycoT.
What is GlycoT’s Technology?
Again developed at UMB and UMCP, their enzymatic glycoengineering technology provides a platform to precisely change and modify the sugars of antibodies. Daichi Sankyo will utilize this cutting-edge technology to prepare new drug candidates.
University IP Success
Phil Robilotto, DO, MBA associate vice president of UMB’s Office of Technology Transfer and director of UM Ventures—a joint technology transfer initiative—commented, “We are very excited to see the growing potential for GlycoT’s glycoengineering technology.” Mr. Robilotto continued, “This is a great example of how university innovators continue to fuel therapeutic development across the globe.”
Founder of GlycoT
Lai-Xi Wang, PhD, Founder and President of GlycoT Therapeutics and UMCP Professor in the Department of Chemistry and Biochemistry, developed the technologies that are the basis for the GlycoT/Daiichi Sankyo license agreement in his lab, first at UMB and later at UMCP.